Neogenomics (NEO) Share-based Compensation (2010 - 2026)

Neogenomics has reported Share-based Compensation for 17 years, with the latest figure at $9.6 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation fell 10.4% year-over-year to $9.6 million; the trailing twelve-month figure through Mar 2026 stood at $40.2 million (up 109.56% YoY), and the FY2025 full-year result was $41.3 million, up 23.65% from the prior year.
• Share-based Compensation for Q1 2026 stood at $9.6 million, up from $8.0 million in the prior quarter.
• The five-year high for Share-based Compensation was $12.2 million in Q2 2025, with the low at $100000.0 in Q2 2024.
• Historically, Share-based Compensation has averaged $7.4 million across 5 years, with a median of $7.9 million in 2024.
• Annual changes were most pronounced in 2023 — Share-based Compensation sank 60.69% — and 2025, when it jumped 12114.0%.
• Neogenomics' Share-based Compensation stood at $4.7 million in 2022, then soared by 49.9% to $7.0 million in 2023, then gained by 19.14% to $8.3 million in 2024, then declined by 3.43% to $8.0 million in 2025, then advanced by 19.82% to $9.6 million in 2026.
• The last three Share-based Compensation figures came in at $9.6 million (Q1 2026), $8.0 million (Q4 2025), and $10.3 million (Q3 2025), per Business Quant data.